Diagnosis and Treatment > Investigation > IGF1

You are looking at 61 - 70 of 70 items

Roberto Salvatori Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Search for other papers by Roberto Salvatori in
Google Scholar
PubMed
Close
,
Adrian F Daly Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium

Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Close
,
Alfredo Quinones-Hinojosa Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Search for other papers by Alfredo Quinones-Hinojosa in
Google Scholar
PubMed
Close
,
Albert Thiry Department of Pathology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium

Search for other papers by Albert Thiry in
Google Scholar
PubMed
Close
, and
Albert Beckers Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium

Search for other papers by Albert Beckers in
Google Scholar
PubMed
Close

Summary

Heterozygous germline inactivating mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene lead to pituitary adenomas that most frequently present in the setting of familial isolated pituitary adenoma syndrome, usually as somatotropinomas and prolactinomas. More recently, they have been found in a significant percentage of young patients presenting with pituitary macroadenoma without any apparent family history. We describe the case of a 19-year-old man who presented with a gigantic somatotropinoma. His family history was negative. His peripheral DNA showed a heterozygous AIP mutation (p.I13N), while tumor tissue only had the mutated allele, showing loss of heterozygosity (LOH) and suggesting that the mutation caused the disease.

Learning points

  • AIP mutations may be observed in sporadic somatotrope adenomas occurring in young patients.

  • LOH is a strong indicator that an AIP variant is disease causing.

  • Somatotrope adenomas in carriers of AIP mutations are generally larger and more difficult to cure.

Open access
Aimee R Hayes Departments of Endocrinology and Neurosurgery, St George Hospital and University of New South Wales, Kogarah, Sydney, New South Wales 2217, Australia

Search for other papers by Aimee R Hayes in
Google Scholar
PubMed
Close
,
Anthony J O'Sullivan Departments of Endocrinology and Neurosurgery, St George Hospital and University of New South Wales, Kogarah, Sydney, New South Wales 2217, Australia

Search for other papers by Anthony J O'Sullivan in
Google Scholar
PubMed
Close
, and
Mark A Davies Departments of Endocrinology and Neurosurgery, St George Hospital and University of New South Wales, Kogarah, Sydney, New South Wales 2217, Australia

Search for other papers by Mark A Davies in
Google Scholar
PubMed
Close

Summary

Pituitary apoplexy is a rare event in pregnancy. A 41-year-old woman with a known pituitary microadenoma presented with visual disturbance and headache during the second trimester of pregnancy. Magnetic resonance imaging (MRI) demonstrated pituitary apoplexy with chiasmal compression. After treatment with corticosteroid therapy, she underwent transsphenoidal excision of the pituitary adenoma. Visual abnormalities were completely restored and pituitary function preserved. There was no evidence of impact on the foetus. The literature on the subject is reviewed with emphasis on the management of the apoplectic patient with mild and stable neuro-ophthalmological signs.

Learning points

  • There are no clear guidelines on the management of pituitary apoplexy in pregnancy. A multidisciplinary approach can minimise morbidity and mortality.

  • Pituitary apoplexy has an unpredictable clinical course and determining which clinical situations warrant early surgery needs to take into consideration the presence and severity of neurological signs and their stability.

  • The management of conscious apoplectic patients with absent or mild and stable neuro-ophthalmological signs is controversial.

Open access
Kamel Mohammedi Assistance Publique Hôpitaux de Paris, Bichat Hospital, Department of Diabetology, Endocrinology and Nutrition, 46 rue Henri Huchard, 75877 Paris Cedex 18, France

Search for other papers by Kamel Mohammedi in
Google Scholar
PubMed
Close
,
Charbel Abi Khalil Assistance Publique Hôpitaux de Paris, Bichat Hospital, Department of Diabetology, Endocrinology and Nutrition, 46 rue Henri Huchard, 75877 Paris Cedex 18, France

Search for other papers by Charbel Abi Khalil in
Google Scholar
PubMed
Close
,
Sophie Olivier Assistance Publique Hôpitaux de Paris, Bichat Hospital, Department of Diabetology, Endocrinology and Nutrition, 46 rue Henri Huchard, 75877 Paris Cedex 18, France

Search for other papers by Sophie Olivier in
Google Scholar
PubMed
Close
,
Imane Benabad Assistance Publique Hôpitaux de Paris, Bichat Hospital, Department of Diabetology, Endocrinology and Nutrition, 46 rue Henri Huchard, 75877 Paris Cedex 18, France

Search for other papers by Imane Benabad in
Google Scholar
PubMed
Close
,
Ronan Roussel Assistance Publique Hôpitaux de Paris, Bichat Hospital, Department of Diabetology, Endocrinology and Nutrition, 46 rue Henri Huchard, 75877 Paris Cedex 18, France

Search for other papers by Ronan Roussel in
Google Scholar
PubMed
Close
, and
Michel Marre Assistance Publique Hôpitaux de Paris, Bichat Hospital, Department of Diabetology, Endocrinology and Nutrition, 46 rue Henri Huchard, 75877 Paris Cedex 18, France

Search for other papers by Michel Marre in
Google Scholar
PubMed
Close

Summary

Hypoglycemia is a common medical emergency. It is the most frequent complication induced by anti-diabetic treatment. However, it can be observed in other conditions unrelated to diabetes such as insulinoma, autoimmune disorders, and neoplasia. Herein, we report the case of a rare cause of severe and recurrent hypoglycemia in a 77-year-old woman with a malignant solitary fibrous tumor (MSFT). A 77-year-old woman was admitted to the emergency department for loss of consciousness induced by severe hypoglycemia. Her standard laboratory findings were unremarkable. HbA1c, albumin, renal, liver, thyroid, and adrenal function tests were normal. Cerebral CT scan was also normal. At the time of confirmed hypoglycemia, the serum level of insulin and C-peptide was low. On the basis of the past medical history and the absence of other comment etiologies, a paraneoplastic cause was suspected. Thus, the diagnosis of a non-islet cell tumor-induced hypoglycemia (NICTH) was established by the presence of incompletely processed precursors of IGF2 (big IGF2) in plasma electrophoresis. However, the IGF1 level was low. Therapy with corticosteroids improved hypoglycemia and clinical symptoms. NICTH is a rare cause of hypoglycemia. It should be considered in patients with mesenchymal or malignant epithelial tumors suffering from recurrent episodes of hypoglycemia. The diagnosis will be established in the case of low serum insulin concentrations and elevated levels of big IGF2. Treatment with corticosteroids, GH, or both can improve hypoglycemic symptoms and restore plasma glucose to normal levels.

Learning points

  • NICTH is a very rare condition that should be considered in patients known to have mesenchymal or malignant epithelial tumors and suffering from recurrent episodes of hypoglycemia.

  • The diagnosis of an NICTH is established on the basis of the hypoinsulinemic hypoglycemia, the MSFT history, and the presence of paraneoplastic secretion of IGF1 or an immature form of IGF2.

  • Treatment with corticosteroids, GH, or both can improve hypoglycemic symptoms and restore plasma glucose to normal levels in NICTH.

Open access
C Mumby
Search for other papers by C Mumby in
Google Scholar
PubMed
Close
,
J R E Davis
Search for other papers by J R E Davis in
Google Scholar
PubMed
Close
,
J Trouillas Department of Histology and Molecular Embryology, Université de Lyon, Lyon, France

Search for other papers by J Trouillas in
Google Scholar
PubMed
Close
, and
C E Higham Department of Endocrinology, Christie Hospital NHS Foundation Trust, Manchester, UK

Search for other papers by C E Higham in
Google Scholar
PubMed
Close

Summary

A 52-year-old lady was referred after a 5 cm left adrenal mass was detected on computed tomography (CT) scanning. She was asymptomatic although was noted to have acromegalic facies. Blood pressure (BP) was normal but plasma normetanephrines were raised to 2.81 mmol/l (<1.09) and urinary normetadrenaline excretion 5.3 μmol/24 h (0–4.3). Adrenal biochemistry screen was otherwise normal. Metaiodobenzylguanidine (MIBG) scan demonstrated uptake in the adrenal lesion. Growth hormone (GH) nadir on oral glucose tolerance test (OGTT) was 2.2 ng/ml with an elevated IGF1 level of 435 ng/ml (72–215), confirming acromegaly biochemically. The remainder of the pituitary screen was normal. A magnetic resonance imaging (MRI) scan of the pituitary revealed an enlarged pituitary gland with a microadenoma/cyst of 2–3 mm in diameter. Alpha blockade was achieved with a titrated dose of phenoxybenzamine before a successful laparoscopic hand-assisted left adrenalectomy. Postoperative biochemical testing revealed a normal plasma normetanephrine level of 0.6 nmol/l (<1.09) and a metanephrine level of 0.35 nmol/l (<0.46 nmol/l). Nadir on OGTT was normal at 0.07 ng/ml with an IGF1 level within the reference range at 111 ng/ml (75–215). Histology demonstrated a well-circumscribed and encapsulated oval mass with microscopic features typical for a phaeochromocytoma. The sections stained strongly positive for GHRH in 20% of cells on immunocytochemistry. Genetic analysis showed no pathogenic mutation. This is a report of the rare condition of a phaeochromocytoma co-secreting GHRH resulting in clinical and biochemical acromegaly. Neuroendocrine tumours can stain positive for GHRH without coexisting acromegaly, but the resolution of patient symptoms and normalisation of serum GH and IGF1 levels following surgery imply that this was functional secretion. Pituitary surgery should be avoided in such cases.

Learning points

  • Incidental findings on imaging require thorough investigation to determine the presence of serious pathology.

  • Acromegaly and phaeochromocytoma are rarely coincident in the same patient. If this occurs, co-secretion of GHRH from the phaeochromocytoma or the presence of underlying genetic abnormalities must be considered.

  • Acromegaly is due to ectopic GHRH-secreting neuroendocrine tumours in <1% of cases, most commonly pancreatic or bronchial lesions.

  • Co-secretion of GHRH from a phaeochromocytoma is extremely rare.

  • In such cases, the pituitary gland may appear enlarged but pituitary surgery should be avoided and surgical treatment of the neuroendocrine tumour attempted.

Open access
Anna Casteràs Department of Endocrinology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Pg. Vall d'Hebron 119-129, Barcelona 08035, Spain

Search for other papers by Anna Casteràs in
Google Scholar
PubMed
Close
,
Jürgen Kratzsch Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany

Search for other papers by Jürgen Kratzsch in
Google Scholar
PubMed
Close
,
Ángel Ferrández Department of Pediatrics, Andrea Prader Centre, Hospital Universitario Miguel Servet, Zaragoza, Spain

Search for other papers by Ángel Ferrández in
Google Scholar
PubMed
Close
,
Carles Zafón
Search for other papers by Carles Zafón in
Google Scholar
PubMed
Close
,
Antonio Carrascosa Department of Pediatrics, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

Search for other papers by Antonio Carrascosa in
Google Scholar
PubMed
Close
, and
Jordi Mesa
Search for other papers by Jordi Mesa in
Google Scholar
PubMed
Close

Summary

Isolated GH deficiency type IA (IGHDIA) is an infrequent cause of severe congenital GHD, often managed by pediatric endocrinologists, and hence few cases in adulthood have been reported. Herein, we describe the clinical status of a 56-year-old male with IGHDIA due to a 6.7 kb deletion in GH1 gene that encodes GH, located on chromosome 17. We also describe phenotypic and biochemical parameters, as well as characterization of anti-GH antibodies after a new attempt made to treat with GH. The height of the adult patient was 123 cm. He presented with type 2 diabetes mellitus, dyslipidemia, osteoporosis, and low physical and psychological performance, compatible with GHD symptomatology. Anti-GH antibodies in high titers and with binding activity (>101 IU/ml) were found 50 years after exposure to exogenous GH, and their levels increased significantly (>200 U/ml) after a 3-month course of 0.2 mg/day recombinant human GH (rhGH) treatment. Higher doses of rhGH (1 mg daily) did not overcome the blockade, and no change in undetectable IGF1 levels was observed (<25 ng/ml). IGHDIA patients need lifelong medical surveillance, focusing mainly on metabolic disturbances, bone status, cardiovascular disease, and psychological support. Multifactorial conventional therapy focusing on each issue is recommended, as anti-GH antibodies may inactivate specific treatment with exogenous GH. After consideration of potential adverse effects, rhIGF1 treatment, even theoretically indicated, has not been considered in our patient yet.

Learning points

  • Severe isolated GHD may be caused by mutations in GH1 gene, mainly a 6.7 kb deletion.

  • Appearance of neutralizing anti-GH antibodies upon recombinant GH treatment is a characteristic feature of IGHDIA.

  • Recombinant human IGF1 treatment has been tested in children with IGHDIA with variable results in height and secondary adverse effects, but any occurrence in adult patients has not been reported yet.

  • Metabolic disturbances (diabetes and hyperlipidemia) and osteoporosis should be monitored and properly treated to minimize cardiovascular disease and fracture risk.

  • Cerebral magnetic resonance imaging should be repeated in adulthood to detect morphological abnormalities that may have developed with time, as well as pituitary hormones periodically assessed.

Open access
Ramez Ibrahim Royal Hallamshire Hospital, Sheffield, UK

Search for other papers by Ramez Ibrahim in
Google Scholar
PubMed
Close
,
Atul Kalhan University Hospital of Wales, Cardiff, UK

Search for other papers by Atul Kalhan in
Google Scholar
PubMed
Close
,
Alistair Lammie Cardiff University, Cardiff, UK

Search for other papers by Alistair Lammie in
Google Scholar
PubMed
Close
,
Christine Kotonya Bronglais Hospital, Aberystwyth, UK

Search for other papers by Christine Kotonya in
Google Scholar
PubMed
Close
,
Ravindra Nannapanenni University Hospital of Wales, Cardiff, UK

Search for other papers by Ravindra Nannapanenni in
Google Scholar
PubMed
Close
, and
Aled Rees Institute of Molecular and Experimental Medicine, Cardiff University, Cardiff, UK

Search for other papers by Aled Rees in
Google Scholar
PubMed
Close

Summary

A 30-year-old female presented with a history of secondary amenorrhoea, acromegalic features and progressive visual deterioration. She had elevated serum IGF1 levels and unsuppressed GH levels after an oral glucose tolerance test. Magnetic resonance imaging revealed a heterogeneously enhancing space-occupying lesion with atypical extensive calcification within the sellar and suprasellar areas. Owing to the extent of calcification, the tumour was a surgical challenge. Postoperatively, there was clinical, radiological and biochemical evidence of residual disease, which required treatment with a somatostatin analogue and radiotherapy. Mutational analysis of the aryl hydrocarbon receptor-interacting protein (AIP) gene was negative. This case confirms the relatively rare occurrence of calcification within a pituitary macroadenoma and its associated management problems. The presentation, biochemical, radiological and pathological findings are discussed in the context of the relevant literature.

Learning points

  • Calcification of pituitary tumours is relatively rare.

  • Recognising calcification in pituitary adenomas on preoperative imaging is important in surgical decision-making.

  • Gross total resection can be difficult to achieve in the presence of extensive calcification and dictates further management and follow-up to achieve disease control.

Open access
Pinaki Dutta Departments of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Search for other papers by Pinaki Dutta in
Google Scholar
PubMed
Close
,
Anuradha Aggarwal Departments of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Search for other papers by Anuradha Aggarwal in
Google Scholar
PubMed
Close
,
Yashpal Gogate Departments of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Search for other papers by Yashpal Gogate in
Google Scholar
PubMed
Close
,
Uma Nahar Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Search for other papers by Uma Nahar in
Google Scholar
PubMed
Close
,
Viral N Shah Departments of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Search for other papers by Viral N Shah in
Google Scholar
PubMed
Close
,
Mandeep Singla Departments of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Search for other papers by Mandeep Singla in
Google Scholar
PubMed
Close
,
N Khandelwal Radiodiagnosis, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Search for other papers by N Khandelwal in
Google Scholar
PubMed
Close
, and
Anil Bhansali Departments of Endocrinology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India

Search for other papers by Anil Bhansali in
Google Scholar
PubMed
Close

Summary

We describe the clinical presentation, diagnostic and management issues in five cases of non-islet cell tumor hypoglycemia (NICTH), diagnosed at a tertiary care institute over a period of 15 years. The clinical, laboratory, and histopathological findings of these patients along with diagnostic utility of IGF2:IGF1 ratio are discussed. The mean age of presentation was 52 years, with a male predominance (3:2). Three patients presented with recurrent episodes of fasting hypoglycemia and it was detected in other two patients during hospitalization. Two patients had acromegaloid features that regressed following treatment. One patient had hypokalemia. Low levels of insulin, C-peptide, GH, and IGF1 were invariably found in all. The IGF2 level was elevated in only one patient; however, IGF2:IGF1 ratio was more than 10 in four of the five patients. The mean tumor size was 16.4 cm and mean weight was 3.6 kg. Four patients had mesenchymal tumors and one had epithelial tumor. NICTH is a rare cause of hypoglycemia. Hypoinsulinemic hypoglycemia with low IGF1 and IGF2:IGF1 ratio more than 10 is suggestive of this entity.

Learning points

  • NICTH should be considered in patients presenting with tumor of mesenchymal origin and hypoglycemia.

  • Hypoinsulinemic hypoglycemia with low IGF1 is a strong biochemical evidence of NICTH.

  • IGF2:IGF1 ratio of more than 10 is a complementary investigation in the absence of an assay facility for IGF2.

Open access
Dominic Cavlan Department of Endocrinology, St Bartholomew's Hospital, West Smithfield, London, UK

Search for other papers by Dominic Cavlan in
Google Scholar
PubMed
Close
,
Shanti Vijayaraghavan Newham University Hospital, Glen Road, London E13 8SL, UK

Search for other papers by Shanti Vijayaraghavan in
Google Scholar
PubMed
Close
,
Susan Gelding Newham University Hospital, Glen Road, London E13 8SL, UK

Search for other papers by Susan Gelding in
Google Scholar
PubMed
Close
, and
William Drake Department of Endocrinology, St Bartholomew's Hospital, West Smithfield, London, UK

Search for other papers by William Drake in
Google Scholar
PubMed
Close

Summary

A state of insulin resistance is common to the clinical conditions of both chronic growth hormone (GH) deficiency and GH excess (acromegaly). GH has a physiological role in glucose metabolism in the acute settings of fast and exercise and is the only anabolic hormone secreted in the fasting state. We report the case of a patient in whom knowledge of this aspect of GH physiology was vital to her care. A woman with well-controlled type 1 diabetes mellitus who developed hypopituitarism following the birth of her first child required GH replacement therapy. Hours after the first dose, she developed a rapid metabolic deterioration and awoke with hyperglycaemia and ketonuria. She adjusted her insulin dose accordingly, but the pattern was repeated with each subsequent increase in her dose. Acute GH-induced lipolysis results in an abundance of free fatty acids (FFA); these directly inhibit glucose uptake into muscle, and this can lead to hyperglycaemia. This glucose–fatty acid cycle was first described by Randle et al. in 1963; it is a nutrient-mediated fine control that allows oxidative muscle to switch between glucose and fatty acids as fuel, depending on their availability. We describe the mechanism in detail.

Learning points

  • There is a complex interplay between GH and insulin resistance: chronically, both GH excess and deficiency lead to insulin resistance, but there is also an acute mechanism that is less well appreciated by clinicians.

  • GH activates hormone-sensitive lipase to release FFA into the circulation; these may inhibit the uptake of glucose leading to hyperglycaemia and ketosis in the type 1 diabetic patient.

  • The Randle cycle, or glucose–fatty acid cycle, outlines the mechanism for this acute relationship.

  • Monitoring the adequacy of GH replacement in patients with type 1 diabetes is difficult, with IGF1 an unreliable marker.

Open access
Rajesh Rajendran Department of Diabetes and Endocrinology, The Ipswich Hospital NHS Trust, Ipswich IP4 5PD, UK

Search for other papers by Rajesh Rajendran in
Google Scholar
PubMed
Close
,
Sarita Naik Department of Diabetes and Endocrinology, Royal United Hospital Bath NHS Trust, Bath BA1 3NG, UK

Search for other papers by Sarita Naik in
Google Scholar
PubMed
Close
,
Derek D Sandeman Department of Diabetes and Endocrinology, University Hospital of Southampton NHS Foundation Trust, Southampton SO16 6YD, UK

Search for other papers by Derek D Sandeman in
Google Scholar
PubMed
Close
, and
Azraai B Nasruddin Department of Diabetes and Endocrinology, University Hospital of Southampton NHS Foundation Trust, Southampton SO16 6YD, UK

Search for other papers by Azraai B Nasruddin in
Google Scholar
PubMed
Close

Summary

We report the use of pasireotide in a rare and unusual case of pituitary macroadenoma co-secreting GH, prolactin and ACTH. A 62-year-old Caucasian man presented with impotence. Clinically, he appeared acromegalic and subsequent investigations confirmed GH excess and hyperprolactinaemia. Magnetic resonance imaging (MRI) of pituitary revealed a large pituitary macroadenoma. He underwent trans-sphenoidal surgery and histology confirmed an adenoma with immunohistochemistry positive for ACTH, GH and prolactin. Acromegaly was not cured following surgery and inadequately controlled despite subsequent octreotide therapy. He underwent further debulking pituitary surgery, following which IGF1 levels improved but still high. This time adenoma cells showed immunohistochemistry positivity for ACTH only, following which subsequent investigations confirmed intermittent hypercortisolaemia compatible with pituitary Cushing's disease. We recommended radiotherapy, but in view of the pluripotential nature of the tumour, we proceeded with a trial of s.c. pasireotide therapy on the basis that it may control both his acromegaly and Cushing's disease. After 3 months of pasireotide therapy, his mean GH and IGF1 levels improved significantly, with improvement in his symptoms but intermittent hypercortisolaemia persists. His glycaemic control deteriorated requiring addition of new anti-diabetic medication. MRI imaging showed loss of contrast uptake within the tumour following pasireotide therapy but no change in size. We conclude that our patient has had a partial response to pasireotide therapy. Long-term follow-up studies are needed to establish its safety and efficacy in patients with acromegaly and/or Cushing's disease.

Learning points

  • Plurihormonal pituitary adenomas are rare and unusual.

  • Patients with pituitary adenomas co-secreting ACTH and GH are more likely to present with acromegaly because GH excess can mask hypercortisolaemia.

  • Pasireotide holds potential where conventional somatostatin analogues are not effective in acromegaly due to higher affinity for somatostatin receptor subtypes 1, 2, 3 and 5.

  • Significant deterioration in glycaemic control remains a concern in the use of pasireotide.

  • Currently, long-term safety and efficacy of pasireotide in patients with acromegaly and/or Cushing's disease are not fully clear.

Open access
Eline van der Valk Diakonessenhuis Utrecht, Department of Internal Medicine, Postbus 80250, 3508 TG Utrecht, The Netherlands

Search for other papers by Eline van der Valk in
Google Scholar
PubMed
Close
,
Tom Tobe Diakonessenhuis Utrecht, Department of Internal Medicine, Postbus 80250, 3508 TG Utrecht, The Netherlands

Search for other papers by Tom Tobe in
Google Scholar
PubMed
Close
,
Aline Stades UMC Utrecht, Department of Endocrinology, Postbus 85500, 3508 GA Utrecht, The Netherlands

Search for other papers by Aline Stades in
Google Scholar
PubMed
Close
, and
Alex Muller Diakonessenhuis Utrecht, Department of Internal Medicine, Postbus 80250, 3508 TG Utrecht, The Netherlands

Search for other papers by Alex Muller in
Google Scholar
PubMed
Close

Summary

A 53-year-old male presented with recurrent calcium oxalate kidney stones as a first sign of underlying acromegaly, which vanished when his acromegaly was controlled. The exact mechanism behind hypercalciuria and urolithiasis in acromegaly is not yet clear. By discussing this case, a short overview of the pathophysiology of hypercalciuria in acromegaly and practical insights are given.

Learning points

  • Hypercalciuria is a common finding in acromegaly.

  • There are only few reports describing hypercalciuric kidney stones in acromegaly.

  • We assume that in acromegaly there is a primary role of IGF1-mediated, PTH-independent increase in calcitriol synthesis resulting in hypercalciuric kidney stones.

Open access